Загрузка...
The safety of JAK-1 inhibitors
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m...
Сохранить в:
| Опубликовано в: : | Rheumatology (Oxford) |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8098103/ https://ncbi.nlm.nih.gov/pubmed/33950230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa895 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|